Company: HURA
Filing Date: 2025-06-06
Form Type: 425
Source: 0001193125-25-137145
Chunk: 28

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-06-06
Form: 425
Chunk 28
---
 pay the sum of $ _____ in immediately available funds to the Company in accordance with the terms of the Warrant. (5) ( If applicable) Pursuant to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares determined in accordance with the terms of the Warrant. The Warrant Shares shall be delivered (check one):

| ☐ to the following DWAC Account Number: _______________________________ |
| ☐ in book-entry form via a direct registration system                   |
| ☐ by physical delivery of a certificate to:                             
 ______________________________________________________                  |
| ______________________________________________________                  |
| ☐ in restricted book-entry form in the Company’s share register         |

(6) By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to the exercise evidenced hereby (i) the Holder is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933, as amended and (ii) the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended) permitted to be owned under Section 11(a)of the Warrant to which this notice relates. (7) The number of shares of Common Stock that the undersigned, together with its Attribution Parties holds and/or beneficially owns and has the right to acquire through the exercise of derivative securities (and any limitations thereon on exercise or conversion) contemporaneously or immediately prior to submitting an Exercise Notice: (Signature must conform in all respects to name of Holder as specified on the face of the Warrant) 14

Exhibit 10.1

SECURITIES PURCHASE AGREEMENT

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of June 2, 2025, by and among TuHURA
Biosciences, Inc., a Nevada corporation (the “Company”), and each of the entities executing signature pages to this Agreement (each, an “Investor” and together, the “Investors”).

WHEREAS, the Company and the Investors are executing and delivering this Agreement in reliance upon the exemption from securities
registration afforded by Section 4(a)(2) of the Securities Act (as defined below) and Rule 506 of Regulation D promulgated under the Securities Act.

WHEREAS, the Company desires to sell to the Investors, and each Investor desires to purchase from